EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year earnings per share growth rate
Latest
4.71%
↑ 102% vs avg
Percentile
P59
Within normal range
Streak
2 qtr
Consecutive growthStable
Average
-202.96%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 4.71% |
| Q3 2025 | 0.00% |
| Q2 2025 | -30.77% |
| Q1 2025 | -1.56% |
| Q4 2024 | -18.52% |
| Q3 2024 | 6.90% |
| Q2 2024 | -5.45% |
| Q1 2024 | -66.67% |
| Q4 2023 | 0.00% |
| Q3 2023 | 45.90% |
| Q2 2023 | -5.17% |
| Q1 2023 | 66.28% |
| Q4 2022 | -251.02% |
| Q3 2022 | 5.77% |
| Q2 2022 | 13.33% |
| Q1 2022 | -1.69% |
| Q4 2021 | -1.72% |
| Q3 2021 | -65.71% |
| Q2 2021 | 30.00% |
| Q1 2021 | 53.27% |
| Q4 2020 | -256.67% |
| Q3 2020 | 71.15% |
| Q2 2020 | 8.77% |
| Q1 2020 | -16.33% |
| Q4 2019 | 32.88% |
| Q3 2019 | -35.19% |
| Q2 2019 | 46.53% |
| Q1 2019 | -60.32% |
| Q4 2018 | 71.43% |
| Q3 2018 | 29.10% |
| Q2 2018 | -306.54% |
| Q1 2018 | -17.69% |
| Q4 2017 | 14.47% |
| Q3 2017 | 3.80% |
| Q2 2017 | -5.33% |
| Q1 2017 | -7553.06% |
| Q4 2016 | 99.07% |
| Q3 2016 | -12.30% |
| Q2 2016 | -24.67% |
| Q1 2016 | 14.77% |